Your browser doesn't support javascript.
loading
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
Murray, Brion W; Rogers, Evan; Zhai, Dayong; Deng, Wei; Chen, Xi; Sprengeler, Paul A; Zhang, Xin; Graber, Armin; Reich, Siegfried H; Stopatschinskaja, Shanna; Solomon, Benjamin; Besse, Benjamin; Drilon, Alexander.
Afiliação
  • Murray BW; Turning Point Therapeutics, San Diego, California. brion.murray@tptherapeutics.com.
  • Rogers E; Turning Point Therapeutics, San Diego, California.
  • Zhai D; Turning Point Therapeutics, San Diego, California.
  • Deng W; Turning Point Therapeutics, San Diego, California.
  • Chen X; Wuxi Biortus Biosciences Co., Ltd., Jiangyin, Jiangsu, China.
  • Sprengeler PA; Turning Point Therapeutics, San Diego, California.
  • Zhang X; Turning Point Therapeutics, San Diego, California.
  • Graber A; Turning Point Therapeutics, San Diego, California.
  • Reich SH; Turning Point Therapeutics, San Diego, California.
  • Stopatschinskaja S; Turning Point Therapeutics, San Diego, California.
  • Solomon B; Peter MacCallum Cancer Center, Melbourne, Australia.
  • Besse B; CLCC Institut Gustave Roussy, Villejuif Cedex, France.
  • Drilon A; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.
Mol Cancer Ther ; 20(12): 2446-2456, 2021 12.
Article em En | MEDLINE | ID: mdl-34625502
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Proteínas de Fusão Oncogênica / Compostos Macrocíclicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Proteínas de Fusão Oncogênica / Compostos Macrocíclicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article